References
- Özyazici M, Gökçe EH, Ertan G. Release and diffusional modelling of metronidazole lipid matrices. Eur J Pharm Biopharm 2006;63:331–339
- Jannin V, Berard V, N’Diaye N, et al. Comparative study of the lubricant performance of Compritol® 888 ATO either used by blending or by hot melt coating. Int J Pharm 2003;262:39–45
- N’Diaye A, Jannin V, Berard V, et al. Comparative study of the lubricant performance of Compritol® HD5 ATO and Compritol® 888 ATO: effect of polyethylene glycol behenate on lubricant capacity. Int J Pharm 2003;254:109–114
- Barthelemy P, Laforet JP, Farah N, Joachim J. Compritol® 888 ATO: an innovative hot-melt coating agent for prolonged-release drug formulations. Eur J Pharm Biopharm 1999;47:87–90
- Faham A, Prinderre P, Farah N, et al. Hot-melt coating technology I: influence of Compritol® 888 ATO and granule size on theophylline release. Drug Dev Ind Pharm 2000;26:167–176
- Hamdani J, Moes AJ, Amighi K. Development and evaluation of prolonged release pellets obtained by the melt pelletization process. Int J Pharm 2002;245:167–177
- Hamdani J, Moes AJ, Amighi K. Development and in vitro evaluation of a novel floating multiple unit dosage form obtained by melt pelletization. Int J Pharm 2006;322:96–103
- Ratsimbazafy V, Bourret E, Brossard C. Drug release from matrix tablets and minitablets containing glycerides. Pharm Ind 1996;58:442–446
- Ratsimbazafy V, Bourret E, Brossard C. Influence of the manufacturing process on the release of proxyphylline from lipid matrices. Pharmazie 1997;52:863–866
- Gu X, Fediuk DJ, Simons FER, Simons KJ. Evaluation and comparison of five matrix excipients for the controlled release of acrivastine and pseudoephedrine. Drug Dev Ind Pharm 2004;30:1009–1017
- Zhang Y, Schwartz JB. Effect of diluents on tablet integrity and controlled drug release. Drug Dev Ind Pharm 2000;26:761–765
- Zhang Y, Tchao R, Schwartz JB. Effect of processing methods and heat treatment on the formation of wax matrix tablets for sustained drug release. Pharm Dev Technol 2001;6:131–144
- Zhang Y, Schwartz JB. Melt granulation and heat treatment for wax matrix-controlled drug release. Drug Dev Ind Pharm 2003;29:131–138
- Obaidat AA, Obaidat RM. Controlled release of tramadol hydrochloride from matrices prepared using glyceryl behenate. Eur J Pharm Biopharm 2001;52:231–235
- Li FQ, Hu JH, Deng JX, et al. In vitro controlled release of sodium ferulate from Compritol® 888 ATO-based matrix tablets. Int J Pharm 2006;324:152–157
- Rao MRP, Ranpise AA, Thanki KC, et al. Effect of processing and sintering on controlled release wax matrix tablets of ketorolac tromethamine. Indian J Pharm Sci 2009;71:538–544
- Savaşer A, Özkan Y, Işimer A. Preparation and in vitro evaluation of sustained release tablet formulations of diclofenac sodium. Il Farmaco 2005;60:171–177
- Jain S. Mechanical properties of powders for compaction and tableting: an overview. Pharm Sci Tech Today 1999;2:20–31
- Moore JW, Flanner HH. Mathematical comparison of curves with an emphasis on dissolution profiles. Pharm Tech 1996;20:64–74
- Bravo SA, Lamas MC, Salomon CJ. Swellable matrices for the controlled-release of diclofenac sodium: formulation and in vitro studies. Pharm Dev Technol 2004;9:75–83
- Mukherjee T, Plakogiannis FM. Effects of process parameters on solid self-emulsifying particles in a laboratory scale fluid bed. Pharm Dev Technol 2012;17:511–520
- Silva OS, Souza CRF, Oliveira WP, Rocha SCS. In vitro dissolution studies of sodium diclofenac granules coated with Eudragit L-30D-55® by fluidized-bed system. Drug Dev Ind Pharm 2006;32:661–667
- Saleem IY, Patel T, Roberts M. Surface coated lactose carrier dry powder inhalation particles using a fluid bed system. J Pharm Pharmacol 2010;62:1301–1302